Lixisenatide reduces postprandial hyperglycaemia via gastrostatic and insulinotropic effects

Diabetes Metab Res Rev. 2015 Sep;31(6):610-8. doi: 10.1002/dmrr.2647. Epub 2015 Apr 23.

Abstract

Background: Lixisenatide is a once-daily, prandial, short-acting glucagon-like peptide-1 receptor agonist. Its main antidiabetic effect is to delay gastric emptying to control postprandial plasma glucose excursions. The dose-response relationship of the integrated insulinotropic and gastrostatic response to lixisenatide in healthy volunteers after a standardized liquid meal was investigated.

Methods: Twenty healthy subjects received acetaminophen 1000 mg with a standardized liquid meal 60 min after a single subcutaneous injection of placebo or lixisenatide 2.5, 5, 10 or 20 µg in randomized order separated by a 2- to 7-day washout. Acetaminophen pharmacokinetics served as a surrogate to assess rate of gastric emptying. Postprandial plasma glucose, insulin, C-peptide and glucagon were assessed for 5 h after the meal test, and lixisenatide pharmacokinetics were determined for 6 h.

Results: After lixisenatide administration and prior to the standardized meal, insulin and C-peptide transiently increased, while fasting plasma glucose decreased in a dose-dependent manner. After the meal, postprandial plasma glucose, insulin and C-peptide were dose proportionally reduced with lixisenatide versus placebo for up to 6 h. Compared with placebo, glucagon levels were transiently lower after any lixisenatide dose, with more sustained reductions after the meal and no apparent dose-related trends. Acetaminophen absorption was significantly reduced and delayed compared with placebo for lixisenatide doses ≥5 µg and demonstrated dose-dependent slowing of gastric emptying. Lixisenatide displayed near dose-proportional exposure, with gastrointestinal events increasing with dose.

Conclusions: Lixisenatide reduced fasting plasma glucose via stimulation of glucose-dependent insulin release and controlled postprandial plasma glucose by delaying gastric emptying, demonstrating it to be a valuable option for overall glycaemic control.

Keywords: gastric emptying; glycaemic control; healthy subjects; lixisenatide; pharmacokinetics; type 2 diabetes mellitus.

Publication types

  • Clinical Trial
  • Clinical Trial, Phase I
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetaminophen / blood
  • Acetaminophen / pharmacokinetics
  • Adult
  • Analgesics, Non-Narcotic / blood
  • Analgesics, Non-Narcotic / pharmacokinetics
  • Blood Glucose / analysis
  • C-Peptide / blood
  • Cross-Over Studies
  • Dose-Response Relationship, Drug
  • Female
  • Gastric Emptying / drug effects*
  • Gastrointestinal Agents / blood
  • Gastrointestinal Agents / pharmacokinetics*
  • Gastrointestinal Agents / pharmacology
  • Glucagon / blood
  • Glucagon / metabolism
  • Glucagon-Like Peptide-1 Receptor / agonists*
  • Glucagon-Like Peptide-1 Receptor / metabolism
  • Humans
  • Hypoglycemic Agents / administration & dosage
  • Hypoglycemic Agents / blood
  • Hypoglycemic Agents / pharmacokinetics*
  • Injections, Subcutaneous
  • Insulin / agonists*
  • Insulin / blood
  • Insulin / metabolism
  • Insulin Secretion
  • Intestinal Absorption / drug effects
  • Male
  • Peptides / administration & dosage
  • Peptides / blood
  • Peptides / pharmacokinetics*
  • Postprandial Period
  • Young Adult

Substances

  • Analgesics, Non-Narcotic
  • Blood Glucose
  • C-Peptide
  • Gastrointestinal Agents
  • Glucagon-Like Peptide-1 Receptor
  • Hypoglycemic Agents
  • Insulin
  • Peptides
  • Acetaminophen
  • lixisenatide
  • Glucagon